Skip to main content

Market Overview

Jefferies Downgrades Catamaran Amid News That Competing Bids For Company Are Unlikely

Share:

Jefferies issued a company note on Tuesday highlighting Catamaran Corp (USA) (NASDAQ: CTRX). Jefferies downgraded Catamaran from Buy to Hold and raised its price target from $58 to $61.50.

Analysts Brian Tanquilut and Jason Plagman wrote, "We expect the UnitedHealth Group Inc. (NYSE: UNH) offer to stand and for the deal to close in 4Q15 as both companies expect. Our view is that Express Scripts Holding Company (NASDAQ: ESRX) is uninterested given the antitrust issues that a deal for CTRX will bring."

Jefferies was surprised by Catamaran's decision to sell itself given that the company was well positioned to gain market share. The current bid for Catamaran is $61.50 per share. Catamaran is believed to be a top notch addition to UnitedHealth Group as it should increase the company's purchasing power and allow them to maintain better relationships with vendors.

Shares of Catamaran recently traded at $59.28, up 0.07 percent.

Latest Ratings for CTRX

DateFirmActionFromTo
Jun 2015UBSDowngradesBuyNeutral
Apr 2015Maxim GroupDowngradesBuyHold
Apr 2015Argus ResearchDowngradesBuyHold

View More Analyst Ratings for CTRX

View the Latest Analyst Ratings

 

Related Articles (CTRX)

View Comments and Join the Discussion!

Posted-In: Brian Tanquilut Jason Plagman JefferiesAnalyst Color Downgrades Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com